Welcome, Guest. Please login or register.
December 04, 2020, 05:46:07 am

Login with username, password and session length


Members
Stats
  • Total Posts: 55052
  • Total Topics: 4816
  • Online Today: 55
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 41
Total: 41

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: FDA Delays Approval of Ocaliva for Fatty Liver Disease  (Read 112 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 772
    • Hep Mag
FDA Delays Approval of Ocaliva for Fatty Liver Disease
« on: November 13, 2020, 11:23:52 am »
The Food and Drug Administration (FDA) indicated in late June that it would not approve Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for the treatment of fibrosis related to non-alcoholic steatohepatitis until more data are available, the company announced. This delays the debut of a first approved therapy for the increasingly common and potentially serious liver condition.

However, as Arun Sanyal, MD, of Virginia Commonwealth University noted at a fatty liver disease symposium sponsored by the Nutrition Obesity Research Center at Harvard, if the agency thought the drug was “ineffective or toxic,” they likely would have stopped an ongoing clinical trial of the drug.

Read more...
https://www.hepmag.com/article/fda-delays-approval-ocaliva-fatty-liver-disease

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.